Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AP Antivirals for treatment of HCV infections
J05AP51 Sofosbuvir and ledipasvir
D10578 Ledipasvir and sofosbuvir <JP/US>
USP drug classification [BR:br08302]
Antivirals
Anti-hepatitis C (HCV) Agents
Ledipasvir/ Sofosbuvir
D10578 Ledipasvir and sofosbuvir
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D10578 Ledipasvir and sofosbuvir
Drug groups [BR:br08330]
Antiviral
DG03198 Anti-HCV agent
D10578 Ledipasvir and sofosbuvir
Transporter substrate
DG01665 ABCB1 substrate
D10578 Ledipasvir and sofosbuvir
DG01913 ABCG2 substrate
D10578 Ledipasvir and sofosbuvir
Drug classes [BR:br08332]
Antiviral
DG03198 Anti-HCV agent
D10578 Ledipasvir and sofosbuvir
Antimicrobials [BR:br08307]
Antivirals
Genome replication inhibitor
HCV NS5A/NS5B inhibitor
D10578 Ledipasvir and sofosbuvir <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10578
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10578
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10578
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10578
Drug metabolizing enzymes and transporters [br08309.html]
Drug transporters
D10578
